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1 
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(CEF)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific output, published on 01 August 2014, replaces the earlier version published on 10 April 
2014*. 
 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of flavouring substances from subgroup 3.2 of 
FGE.19 in the Flavouring Group Evaluation 215 (FGE.215). The Flavour Industry has provided in vitro 
genotoxicity studies for the representative substances in FGE.215, namely  4-phenylbut-3-en-2-one [FL-no: 
07.024] and 1-(4-methoxyphenyl)pent-1-en-3-one [FL-no: 07.030]. Based on these genotoxicity data, the Panel 
concluded that the genotoxicity concern could not be ruled out and in vivo genotoxicity data are requested. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF) was asked to deliver a scientific opinion on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate seven α,β-unsaturated substances in 
the Flavouring Group Evaluation 215 (FGE.215) using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000.  
The present FGE.215, corresponding to subgroup 3.2 of FGE.19, concerns six cinnamyl ketones with 
the α,β-unsaturation in the side-chain [FL-no: 07.024, 07.027, 07.030, 07.046, 07.049 and 07.206] and 
one precursor [FL-no: 02.066] for such ketones. The seven substances under consideration in FGE.215 
are listed in Table 3.  
The  α,β-unsaturated  ketone  structure is a structural alert for genotoxicity and the data previously 
available did not rule out the concern for genotoxicity for these seven flavouring substances. 
The Flavour Industry has now submitted in vitro data for two representative substances (4-phenylbut-
3-en-2-one [FL-no:  07.024] and 1-(4-methoxyphenyl)pent-1-en-3-one [FL-no:  07.030])  which are 
going to cover the evaluation of the other five substances in this subgroup 3.2 of FGE.19. 
The Panel has evaluated these data and concluded that the genotoxicity concern could not be ruled out. 
To further assess the genotoxic potential of both representative substances (4-phenylbut-3-en-2-one 
[FL-no: 07.024]  and  1-(4-methoxyphenyl)pent-1-en-3-one [FL-no: 07.030])  of  subgroup 3.2 of 
FGE.19, a combined in vivo micronucleus and Comet assays in liver and duodenum are requested. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavouring is regulated under Regulation (EC) No 1334/2008
4 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with  flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation an evaluation and 
approval are required for flavouring substances. 
The Union List of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6. 
At the 26
th  Plenary meeting of the AFC Panel on 27 - 29 November 2007, EFSA discussed the 
flavouring group evaluation 19 (FGE.l9). FGE.19 contains those flavouring substances which are α,β-
unsaturated aldehydes or ketones and their precursors which could give rise to such carbonyl 
substances  via  hydrolysis  and/or  oxidation.  The  α,β-unsaturated aldehyde and ketone structure is 
considered to be a structural alert for genotoxicity. FGE.l9 was divided into subgroups. For subgroup 
3.2 EFSA concluded that there is a need for additional information before conclusions on the 
substances in this subgroup can be reached. 
Genotoxicity data on two representative materials, namely 4-phenylbut-3-en-2-one [FL-no: 07.024] 
and 1-(4-methoxyphenyl)pent-1-en-3-one  [FL-no:  07.030]  from subgroup 3.2, have now been 
submitted by the European Flavour Association (EFFA). This information is intended to cover the re-
evaluation of the above mentioned substances and of the following five substances from FGE.19 
subgroup 3.2: 
•  4-Phenylbut-3-en-2-ol [FL-no: 02.066]  
•  3-Methyl-4-phenylbut-3-en-2-one [FL-no: 07.027] 
•  1-(4-Methoxyphenyl)-4-methylpent-1-en-3-one [FL-no: 07.049] 
•  4-(2,3,6-Trimethylphenyl)but-3-en-2-one [FL-no: 07.206] 
•  Vanillylidene acetone [FL-no: 07.046] 
The Commission asks  EFSA  to  evaluate  this  new  information  and  depending  on  the  outcome 
proceed to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following seven substances included in subgroup 3.2 of FGE.19: 4-phenylbut-3-en-
2-ol [FL-no: 02.066], 4-phenylbut-3-en-2-one [FL-no: 07.024], 3-methyl-4-phenylbut-3-en-2-one [FL-
no: 07.027], 1-(4-methoxyphenyl)pent-1-en-3-one [FL-no: 07.030], vanillylidene acetone [FL-no: 
07.046], 1-(4-methoxyphenyl)-4-methylpent-1-en-3-one [FL-no:  07.049] and 4-(2,3,6-
trimethylphenyl)but-3-en-2-one [FL-no: 07.206] in accordance with Commission Regulation (EC) No 
1565/2000. 
                                                       
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p.1-
161. 
6  Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. Flavouring Group Evaluation 215 
 
EFSA Journal 2014;12(4):3623  5 
HISTORY OF FGE.19 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008a). 
The  α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity  (EFSA, 
2008a). The Panel noted that there were limited genotoxicity data on these flavouring substances but 
that positive genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the Panel 
considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and decided not 
to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b)  and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008a) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established: 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225. 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further scrutiny of the data should take place before requesting additional  data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a 
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the 
Procedure. For all or some of the substances in the remaining FGEs, FGE.201, 203, 210, 212, 213, 
216, 217 and 220 the genotoxic potential could not be ruled out. 
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data were requested, EFSA worked out a list of representative 
substances for each subgroup (EFSA, 2008c). Likewise an EFSA genotoxicity expert group has 
worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b).  
The Flavouring industry has now submitted additional genotoxicity  data  according to the list of 
representative substances and test strategy for each subgroup and the present FGE concerns the 
evaluation of these data. Flavouring Group Evaluation 215 
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ASSESSMENT 
1.  Presentation of the Substances in the Flavouring Group 
1.1.  Description 
The present Flavouring Group Evaluation 215 (FGE.215), corresponding to subgroup 3.2 of FGE.19, 
concerns six cinnamyl ketones with the α,β-unsaturation in the side-chain [FL-no: 07.024, 07.027, 
07.030, 07.046, 07.049 and 07.206] and one precursor for such ketones [FL-no: 02.066]. The seven 
substances under consideration in FGE.215 are listed in Table 3.  
Six of the flavouring substances were previously evaluated by the JECFA (JECFA, 2002). A summary 
of their current evaluation status by the JECFA and the outcome of this consideration is presented in 
Table 4. 
The α,β-unsaturated ketone structure is a structural alert for genotoxicity (EFSA, 2008a) and the data 
on genotoxicity previously available did not rule out the concern for genotoxicity for these seven 
flavouring substances. 
1.2.  Representative Substance for Subgroup 3.2 
The Panel has identified two substances in subgroup 3.2 which will represent the other five substances 
in this subgroup (EFSA, 2008c). For these substances genotoxicity data, according to the test strategy 
(EFSA, 2008b), have been requested. The representative substances are shown in Table 1. 
 
Table 1:   Representative Substances for Subgroup 3.2 of FGE.19 (EFSA, 2008c) 
FL-no  
JECFA-no  
EU Register name   Structural formula  
07.024 
820 
4- Phenylbut-3-en-2-one   
O
(E)-isomer shown  
07.030 
826 
 
1-(4-Methoxyphenyl)pent-1-en-3-one   
O
O
(E)-isomer shown  
 Flavouring Group Evaluation 215 
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2.  Genotoxicity Data on the Representative Substances of Subgroup 3.2 
The data on genotoxicity, submitted by the Industry (EFFA, 2013), for the representative substances of 
this subgroup are listed in Table 2. 
Table 2:   Data Submitted for Representative substances of FGE.215 
FL-no  
JECFA-
no  
EU Register name   Data submitted  
07.024 
820 
4-Phenylbut-3-en-2-one  Ames test, S. typhimurium TA98, TA100, TA1535, 
TA1537 and TA102, ± S9-mix (Lillford, 2009) 
in vitro Micronucleus assay in human peripheral blood 
lymphocytes, 3+21 hours with recovery ± S9-mix and 
24+0 hours without recovery – S9-mix (Stone, 2011; 
Watters, 2013) 
07.030 
826 
 
1-(4-Methoxyphenyl)pent-1-en-3-
one 
Ames test, S. typhimurium TA98, TA100, TA1535, 
TA1537 and TA102, ± S9-mix (Bowen, 2011) 
in vitro Micronucleus assay in human peripheral blood 
lymphocytes, 3+21 hours with recovery  ± S9-mix and 
24+0 hours without recovery – S9-mix (Stone, 2012) 
 
2.1.  In vitro Data 
2.1.1.  Bacterial Reverse Mutation Assay 
4-phenylbut-3-en-2-one [FL-no: 07.024] 
Ames assays were conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 and 
TA102 to assess the mutagenicity of 4-phenylbut-3-en-2-one [FL-no: 07.024] (purity 99.6 %), both in 
the absence and in the presence of metabolic activation by an Aroclor 1254-induced rat liver 
postmitochondrial fraction (S9-mix) in three separate experiments using both standard plate 
incorporation and modified pre-incubation treatments (Lillford, 2009). Study design complies with 
OECD Guideline 471 (OECD, 1997). An initial toxicity range-finding experiment was carried out in 
triplicate using the plate incorporation method in the presence and absence of S9-mix, for the TA100 
strain only, at concentrations of 1.6, 8, 40, 200, 1000 and 5000 μg/plate, plus negative vehicle and 
positive controls. Evidence of toxicity in the form of complete killing of the background lawn was 
observed at 5000 μg/plate in the absence and presence of S9-mix. Since mutagenicity was observed at 
40 μg/plate and above in the presence of S9-mix, the strain was included in experiment 1 for further 
assessment. 
In experiment 1, S. typhimurium strains TA98, TA1535, TA1537 and TA102 were incubated with 1.6, 
8, 40, 200, 1000 and 3000 μg/plate of 4-phenylbut-3-en-2-one in the absence and presence of S9-mix. 
Strain TA100 was incubated with the same concentrations in the absence of S9-mix, but with a highest 
concentration of 5000 μg/plate in the presence of S9-mix. The standard plate incorporation method 
was employed. Evidence of toxicity was observed at 3000 μg/plate in TA100 in the absence of S9-mix 
and in all other strains in the absence and presence of S9-mix, in the form of a slight thinning of the 
background bacterial lawn or complete killing of the bacteria. A reduction in the numbers of revertants 
and/or a slight thinning of the background bacterial lawn was also observed at 1000 μg/plate in strain 
TA1535 in the absence of S9-mix. Complete killing was observed at 5000 μg/plate in strain TA100 in 
the presence of S9-mix. A statistically significant concentration-related increase in mutation rate was 
observed in strain TA100 at 40 μg/plate and above in the presence of S9-mix. Flavouring Group Evaluation 215 
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In experiment 2, S. typhimurium strains TA98, TA100, TA1535, TA1537 and TA102 were treated 
with 93.75, 187.5, 375, 750, 1500 and 3000 μg/plate of 4-phenylbut-3-en-2-one in the absence and in 
the presence of S9-mix, to assess mutagenicity close to the limits of toxicity. The assays run in the 
presence of S9-mix were further modified by the inclusion of a pre-incubation step (60 minutes). 
Evidence of toxicity ranging from a marked reduction in revertant numbers and/or slight thinning of 
the bacterial lawn to a complete killing of the test bacteria was observed at 750 and/or 1500 and/or 
3000 μg/plate in the absence and presence of S9-mix. Treatments of strain TA100 in the presence of 
S9-mix at concentrations of 375 μg/plate and above showed a statistically significant concentration- 
related increase in revertant mutations (p ≤ 0.01).  
To further explore the increase in mutations reported in S. typhimurium strain TA100, experiment 3 
was performed in all tester strains only in the presence of S9-mix, using the pre-incubation method, at 
concentrations of 46.88 - 1500 μg/plate of 4-phenylbut-3-en-2-one. Evidence of cytotoxicity in the 
form of complete killing of the test bacteria was observed at 1500 μg/plate in all strains. Treatments of 
the TA100 strain in the presence of S9-mix at concentrations equal to or higher than 187.5 μg/plate 
showed a statistically significant increase in revertant mutations (p ≤ 0.01).  
Although there was evidence of toxicity towards all the bacterial strains tested, it was concluded that 
4-phenylbut-3-en-2-one induced reproducible, concentration-related and statistically significant 
mutations in strain TA100 of S. typhimurium in the presence of metabolic activation. It did not induce 
mutations in any other strain when tested under the conditions of this study. These conditions included 
treatments at concentrations up to either the limit of toxicity  or  5000  μg/plate  (the  maximum 
recommended concentration according to current regulatory guidelines), in the absence and in the 
presence of a rat liver metabolic activation system (S9-mix) (Lillford, 2009). 
1-(4-Methoxyphenyl)pent-1-en-3-one [FL-no: 07.030] 
The mutagenicity of 1-(4-methoxyphenyl)pent-1-en-3-one  (purity 98  %)  was assessed in S. 
typhimurium strains TA98, TA100, TA1535, TA1537 and TA102, both in the absence and in the 
presence of metabolic activation by an Aroclor 1254-induced rat liver post-mitochondrial fraction (S9-
mix), in three separate experiments using both standard plate incorporation and modified pre-
incubation treatments (Bowen, 2011).  Study design complies with OECD Guideline 471 (OECD, 
1997). 
In experiment 1, all S. typhimurium strains were incubated with 0.32, 1.6, 8, 40, 200, 1000 and 5000 
μg/plate of 1-(4-methoxyphenyl)pent-1-en-3-one, in the absence and presence of S9-mix. Toxicity was 
observed in the form of slight thinning of background bacteria lawn and reduced numbers of revertants 
at 1000 μg/plate in strains TA1537 and TA102 and complete killing of bacteria was observed at 5000 
μg/plate in all strains, in the absence and presence of S9-mix. No increases in revertants were observed 
in any strain under any treatment condition. 
In experiment 2, all tester strains were treated with 1-(4-methoxyphenyl)pent-1-en-3-one in the 
absence and in the presence of S9-mix at more narrow concentration intervals. All strains were treated 
with concentrations of 156.3, 312.5, 625, 1250, 2500 and 5000 μg/plate and strains TA1537 and 
TA102 were also treated at a lower concentration of 78.13. The maximum test concentration of 5000 
μg/plate  was  retained  for  all  strains,  in  order  to  examine  more  closely  the  ability  of  1-(4-
methoxyphenyl)pent-1-en-3-one to induce mutations at concentrations approaching the maximum test 
concentration and/or toxicity limit. In addition, all treatments in the presence of S9-mix were further 
modified by the inclusion of a pre-incubation step. Evidence of toxicity in the form of thinning of the 
background lawn and/or a reduction in revertant numbers to a complete killing of the test bacteria was 
observed at 625 μg/plate and above in strains TA1535, TA1537 and TA102 in the presence of S9-mix, 
at 1250 μg/plate and above in strains TA1537 and TA102 in the absence of S9-mix and TA100 in the 
presence of S9-mix, and at 2500 μg/plate and above in strains TA98 in the absence and presence of 
S9-mix, and TA100 and TA1535 in the absence of S9-mix. No increases in revertants were observed 
in any strain under any treatment condition. Flavouring Group Evaluation 215 
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Experiment 3 was performed in strains TA1535 and TA1537 in the presence of S9-mix, using a pre-
incubation methodology, due to the toxicity reported in experiment 2. The maximum test 
concentration was reduced to  2500  μg/plate  based  on  toxicity  observed  previously.  Narrowed 
concentration intervals were employed including 19.53, 39.06, 78.13, 156.3, 312.5, 625, 1250 and 
2500 μg/plate. Under these conditions, evidence of toxicity was observed at 625 μg/plate and above in 
both of these strains in the presence of S9-mix, ranging from thinning of the background bacteria lawn 
and/or a reduction in revertant numbers to a complete killing of the test bacteria. Consistent with 
previous experiments, no increases in revertants were observed in either strain under these treatment 
conditions. 
It was concluded that 1-(4-methoxyphenyl)pent-1-en-3-one did not induce mutation in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. typhimurium when tested under 
the conditions of this study. These conditions included treatments at concentrations up to 5000 
μg/plate (the maximum recommended concentration according to current regulatory guidelines), in the 
absence and in the presence of a rat liver metabolic activation system. 
2.1.2.  Micronucleus Induction Assay 
4-phenylbut-3-en-2-one [FL-no: 07.024] 
4-Phenylbut-3-en-2-one [FL-no: 07.024] (purity 99 %) was assayed for the induction of chromosome 
damage and potential clastogenic and/or aneugenic events in mammalian cells in vitro by examining 
its effect on the frequency of micronuclei in cultured human peripheral blood lymphocytes (whole 
blood cultures pooled from 2 healthy male donors) in three separate trials, treated in the absence and 
presence of S9-mix (Stone, 2011). Study design complies with OECD Guideline 487 (OECD, 2010). 
In a range-finding experiment, 4-phenylbut-3-en-2-one was added at concentrations of 5.304, 8.840, 
14.73, 24.56, 40.93, 68.21, 113.7, 189.5, 315.8, 526.3, 877.2 and 1462 μg/ml at 48 hours following 
culture initiation (stimulation by phytohaemagglutinin) either for 3 hours treatment plus 21 hours 
recovery in the absence or presence of S9-mix, or for 24 hours treatment without recovery in the 
absence of S9-mix. In the assay with 3 hours treatment and 21 hours of recovery, a steep increase in 
cytotoxicity  was  observed  between  the  concentrations  of  24.56  and  40.93  μg/ml  (32 and 72  %, 
respectively) in the absence of S9-mix, and between the concentrations of 40.93, 68.21 and 113.7 
μg/ml (18, 35 and 87 %, respectively) in the presence of S9-mix. In the assay of 24 hours treatment 
with no recovery period, a steep increase in cytotoxicity was observed between the concentrations of 
8.840, 14.73 and 24.56 μg/ml (13, 54 and 92 %, respectively). According to the study report, in the 
cytotoxicity range-finder  experiment,  the pH and osmolality were  measured  in the  medium  after 
treatment of cells. Their values remained within physiological limits, however, the details of the data 
were not reported. Positive and negative control substances produced the expected responses. 
In the main micronucleus experiment, three separate trials were conducted for each set of treatment 
conditions (3 + 21 hours recovery in the absence and presence of S9-mix  and 24 hours without 
recovery in the absence of S9-mix) in order to identify an appropriate range of concentrations that 
would include adequate level of cytotoxicity. 
In the first trial, treatment was conducted for 3 + 21 hours recovery in the absence of S9-mix at 
concentrations of 5, 10, 15, 20, 25, 27.5, 30, 32.5, 35, 37.5, 40 and 50 μg/ml 4-phenylbut-3-en-2-one 
were selected for micronucleus analysis based on the cytotoxicity observations of the range-finding 
experiment. No suitable maximum concentrations could be selected due to insufficient cytotoxicity (< 
30 % at the highest concentration). A second trial with treatment for 3 + 21 hours recovery in the 
absence of S9-mix was conducted using 4-phenylbut-3-en-2-one concentrations of 10, 15, 20, 25, 30, 
35, 40, 50, 55, 60, 65, 70, 75, 80 and 100 μg/ml. No suitable range could be selected due to a steep 
increase in cytotoxicity between the concentrations of 35 and 40 μg/ml (33 and 65 %, respectively). In 
a third trial using a range between 10 - 100 μg/ml, with more narrowly spaced concentration intervals 
of 2.5 μg/ml between 25 and 40 μg/ml, the observed cytotoxicity range was considered adequate. 
Concentrations of 30, 40 and 50 μg/ml were selected from the third trial for analysis of micronucleus Flavouring Group Evaluation 215 
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induction by 4-phenylbut-3-en-2-one treatment for 3 + 21 hours recovery in the absence of S9-mix. 
The frequency of  micronucleated binucleate (MNBN)  cells was similar to vehicle controls at all 
concentrations tested (with cytotoxicity of 14, 32 and 56 %, respectively). 
For treatment with 4-phenylbut-3-en-2-one for 3 + 21 hours recovery in the presence of S9-mix, a 
suitable concentration range could not be identified in the first of three trials that included a range of 
20 - 120 μg/ml, spaced at 10 μg/ml intervals (and 5 μg/ml intervals between 70 - 90 μg/ml), due to a 
steep increase in cytotoxicity (38, 47 and 67 % at concentrations of 85, 90 and 100 μg/ml). Using the 
same concentration range, 20 - 120 μg/ml, a second trial was performed with more narrowly spaced 
intervals of 2.5 μg/ml between 85 and 100 μg/ml. Due to steep concentration-related toxicity, the trial 
was repeated a third time. The third trial conducted at the same concentration range (20 - 120 μg/ml) 
resulted in insufficient cytotoxicity levels (48 % at the highest concentration), unlike those observed in 
the second trial.  Therefore, concentrations from trial two  were selected for micronuclei analysis. 
Although cytotoxicity observed in the second trial was not within the desired target range (50 – 60 %), 
the reduction of 65 % in replicative index achieved at 85 μg/ml was considered acceptable. The 
following concentrations were selected for micronucleus  analysis:  40,  70,  80  and  85  μg/ml.  The 
frequency of MNBN cells was similar to vehicle controls at all concentrations scored (cytotoxicity of 
15, 27, 42 and 65 %, respectively).  
Cultures were also treated for 24 + 0 hours in the absence of S9-mix at concentrations of 12, 14, 17.5 
and 20 μg/ml (with cytotoxicity of 11, 20, 46 and 60 %, respectively), selected from a single trial 
conducted at concentration range of  2 - 20  μg/ml  of 4-phenylbut-3-en-2-one. The frequencies of 
MNBN cells were similar to those observed in concurrent vehicle controls at all concentrations 
analysed. All frequencies of MNBN fell within normal ranges based on historical control data. 
In this study, 4-phenylbut-3-en-2-one did not induce micronuclei in cultured human peripheral blood 
lymphocytes when tested up to the limits of cytotoxicity for 3 + 21 hours in the absence and presence 
of rat liver metabolic activation (S9-mix), or for 24 + 0 hours in the absence of S9-mix (Stone, 2011). 
The inconsistent cytotoxicity curves generated in the first micronucleus study for 4-phenylbut-3-en-2-
one could not be easily explained, and on that basis a second study was initiated.  
4-Phenylbut-3-en-2-one (purity 99.9 %) was reassessed in vitro for the induction of chromosome 
damage and potential clastogenic and/or aneugenic events in mammalian cells by examining its effect 
on the frequency of micronuclei in cultured human peripheral blood lymphocytes (pooled blood of 2 
healthy female donors in three separate experiments and of two male donors in a single experiment) 
treated in the absence and presence of S9-mix (Watters, 2013). 
In a range-finding experiment, 4-phenylbut-3-en-2-one was added at concentrations of 2.5, 5.0, 10.0, 
20.0, 30.0, 40.0, 50.0, 60.0, 80.0, 100.0, 120.0 and 150.0 μg/ml at 48 hours following culture initiation 
(stimulation by phytohaemagglutinin) either for 3 hours treatment plus 21 hours recovery in the 
absence or presence of S9-mix, or for 24 hours treatment without recovery in the absence of S9-mix. 
In the assay with 3 hours treatment and 21 hours of recovery, a steep increase in cytotoxicity was 
observed between the concentrations of 40.0 and 50.0 μg/ml (16 and 65 % toxicity, respectively) in the 
absence of S9-mix, and between the concentrations of 80.0 and 100.0 μg/ml (6 and 55 % toxicity, 
respectively) in the presence of S9-mix. In the assay of 24-hour treatment with no recovery period, a 
steep increase in cytotoxicity was observed between the concentrations of 10.0 and 20.0 μg/ml (11 and 
89 %, respectively). According to the study report, in the cytotoxicity range-finder experiment, the pH 
and osmolality were measured in the medium after treatment of cells. Their values remained within 
physiological limits. Positive and negative control substances produced the expected responses. 
In the first trial, treatment was conducted for 3 + 21 hours recovery in the absence of S9-mix and 
concentrations of 30, 40, 44 and 46 μg/ml were selected for analysis of micronucleus induction. The 
frequency of MNBN cells was similar to vehicle controls at all concentrations tested (with cytotoxicity 
of 5, 32, 44 and 50 %, respectively). The frequencies of MNBN in the vehicle control was above the Flavouring Group Evaluation 215 
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historical control range. For treatment with 4-phenylbut-3-en-2-one for 3 + 21 hours recovery in the 
presence of S9-mix, concentrations of 85, 95, 100 and 105 μg/ml  were chosen for micronucleus 
analysis, and the frequency of MNBN cells was statistically significant and higher than vehicle 
controls at all concentrations scored (cytotoxicity of 8, 28, 41 and 51 % respectively). Cultures were 
also treated for 24 + 0 hours in the absence of S9-mix and concentrations of 8, 13, 14 and 15 μg/ml 
(with cytotoxicity of 0, 29, 45 and 59 %, respectively) were chosen for micronucleus analysis. The 
frequencies of MNBN cells were similar to those observed in concurrent vehicle controls at all 
concentrations analysed. All frequencies of MNBN fell within normal ranges based on historical 
control data. 
In the first trial, the micronucleus data for both of the 3 + 21 hours treatments showed inconsistent 
MNBN cell frequencies between replicate cultures in all four 4-phenyl-3-buten-2-one concentrations 
analysed and the concurrent vehicle control when scored by Analyst 1 (statistically significant 
heterogeneity was apparent; p ≤ 0.05). Therefore, the slides were sent to a peer review Analyst 
(Analyst 2) for re-analysis. A comparison of the analysts results is as follows: 
Analyst 1: Treatment of cells with 4-phenyl-3-buten-2-one for 3 + 21 hours in the absence of S9-mix 
resulted  in frequencies of MNBN cells that were inconsistent between replicate cultures for all 
concentrations analysed. The MNBN cell frequency of a single replicate culture from the concurrent 
vehicle control and in each of the four test article concentrations analysed exceeded the normal range 
(0.1 - 1.1 % MNBN cells). The mean MNBN cell frequency for the vehicle control and each test 
article marginally exceeded the normal range. 
Analyst 2: Treatment of cells for 3 + 21 hours in the absence of S9-mix resulted in frequencies of 
MNBN cells that were significantly higher (p ≤ 0.01) than those observed in concurrent vehicle 
controls for an intermediate and the highest concentration analysed (40 and 46 μg/ml, respectively). 
The MNBN cell frequency of both cultures at 40 and 46 μg/ml exceeded the normal range. Single 
replicate cultures also exceeded the normal range in the concurrent vehicle control and the other two 
concentrations analysed (30 and 44 μg/ml). 
As the MNBN cell frequency of one replicate culture of the vehicle control exceeded the normal range 
when scored by both analysts, the validity of the dataset was considered questionable. Therefore, a 
confirmatory experiment was performed for the 3 + 21 hours treatment without S9-mix using the same 
concentrations (trial 2). These data would also aid biological relevance interpretation of the test 
article-related increases in MNBN cell frequency determined by Analyst 2. 
Treatment of cells with 4-phenyl-3-buten-2-one in the absence of S9-mix  in trial 2 resulted in 
frequencies of MNBN cells that were significantly higher (p ≤ 0.05) than those observed in concurrent 
vehicle controls at the lowest and two highest concentrations analysed (30, 46 and 48 μg/ml, 
respectively). The MNBN cell frequency of both treated cultures at 46 and 48 μg/ml exceeded the 
normal range. 
Data obtained from the treatment of cells (female donors) for 3 + 21 hours in the presence of S9-mix 
were also scored by 2 Analysts. The data from both Analysts showed that the treatment of cells for 
3 + 21 hours in the presence of S9-mix resulted in frequencies of MNBN cells that were significantly 
higher (p ≤ 0.05) than those observed in concurrent vehicle controls for all concentrations analysed. 
The MNBN cell frequency of all but a single replicate culture at the lowest concentration analysed (by 
Analyst 1) exceeded the normal range. Although it was noted that Analyst 2 scored higher MNBN cell 
frequencies compared to Analyst 1, both datasets demonstrated increases in MNBN cell frequencies 
above the normal range for all concentrations analysed, indicative of a positive result. 
These data confirmed that the increases in MNBN cell frequency observed in trial 1 were test article 
related despite some inconsistencies in micronucleus data. These results are, however,  entirely 
inconsistent with those previously collected (Stone, 2011).  Flavouring Group Evaluation 215 
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The authors tried to attribute these inconsistencies to the use of pooled blood collected from male 
donors in the study by Stone (Stone, 2011), compared to the study by Watters (Watters, 2013)  where 
pooled blood collected from female donors  was used. On this basis  they  investigated  possible 
differences in outcomes due to sex differences in donors, performing a third trial  for 3 + 21 hours in 
the presence of S9-mix using different replicate cultures prepared from pooled blood obtained by 
either two female donors or two male donors treated at the same concentrations for scoring as in trials 
1 and 2. The MNBN cell frequencies of treated cultures at 95, 105 and 110 μg/ml exceeded the normal 
range and were significantly higher (p ≤ 0.001) than those observed in concurrent vehicle controls for 
both replicate cultures obtained from male and female donors.  Results obtained indicate that  sex 
differences did not play a role on the study outcome. Inconsistencies in the cytotoxicity and MNBN 
cell frequencies of treated cultures between  the two studies could be ascribed, plausibly, to 
methodological differences since in the study by Stone (Stone, 2011) gentamicin at 50 μg/ml in culture 
medium was used instead of 0.52 % penicillin/streptomycin, as foreseen by standard protocol, which 
is considered a shortcoming. 
4-Phenylbut-3-en-2-one was tested on pooled blood lymphocytes cultures from female donors for 24 
hours with no recovery period, in the absence of S9-mix. Concentrations of 4-phenylbut-3-en-2-one at 
8, 13, 14 and 15 μg/ml were selected for micronucleus analysis corresponding to a cytotoxicity of 0, 
29, 45 and 59 %, respectively. Frequencies of MNBN cells were not statistically significant higher 
than those observed in concurrent vehicle controls for all concentrations analysed (Watters, 2013).  
In conclusion, in this study 4-phenylbut-3-en-2-one did induce micronuclei in cultured human 
peripheral blood lymphocytes when tested up to the limits of cytotoxicity for 3 + 21 hours in the 
absence and presence of rat liver metabolic activation (S9-mix). In the same test system, 4-phenylbut-
3-en-2-one did not induce micronuclei following 24 + 0 hours treatment in the absence of S9-mix, 
when analysed up to cytotoxic concentrations.  
1-(4-Methoxyphenyl)pent-1-en-3-one [FL-no: 07.030] 
1-(4-Methoxyphenyl)pent-1-en-3-one (purity 98 %) was assayed for the induction of chromosome 
damage and potential clastogenic and/or aneugenic events in mammalian cells in vitro by examining 
its effect on the frequency of micronuclei in cultured human peripheral blood lymphocytes (whole 
blood cultures pooled from 2 healthy female volunteers) in a single experiment, treated in the absence 
and presence of S9-mix (Stone, 2012). Study design complies with OECD Guideline 487 (OECD, 
2010). 
In a range-finding experiment, 1-(4-methoxyphenyl)pent-1-en-3-one was added at concentrations of 
6.9, 11.5, 19.17, 31.95, 53.24, 88.74, 147.9, 246.5, 410.8, 684.7, 1141 and 1902 μg/ml at 48 hours 
following culture initiation (stimulation by phytohaemagglutinin) either for 3 hours treatment plus 21 
hours recovery in the absence or presence of S9-mix, or for 24 hours treatment without recovery in the 
absence of S9-mix. In the assay with 3 hours treatment and 21 hours of recovery, cytotoxicity was 
observed at concentrations of 88.74 μg/ml (32 %) and above in the absence of S9-mix, and 53.24 
μg/ml  (24 %) and above in the presence of S9-mix. In the assay of 24 hours  treatment with no 
recovery period, a steep increase in cytotoxicity was observed already at the lowest concentration 
(27 %). Precipitation was observed at 147.9 μg/ml and above. The replication index could not be 
measured at 410 μg/ml and above in the pulse assays and at 246.5 in the 24-hour treatment assay. 
According to the study report, in the cytotoxicity range-finder experiment, the pH and osmolality were 
measured in the medium after treatment of cells. Their values remained within physiological limits. 
Positive and negative control substances produced the expected responses. 
Treatment of cells with 1-(4-methoxyphenyl)pent-1-en-3-one was conducted for 3 + 21 hours at 
concentrations of 60, 100, 110, 120 and 130 μg/ml in the absence of S9-mix (cytotoxicity of 12, 30, 
51, 60 and 46 %, respectively) and 90, 150, 160 and 180 μg/ml in the presence of S9-mix (cytotoxicity 
of 2, 28, 49 and 61 %, respectively). The concentrations were selected from a single trial covering the 
range 15 - 175  μg/ml  in the absence of S9-mix  and 15  -  225  μg/ml  in the presence of S9-mix. Flavouring Group Evaluation 215 
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Treatment resulted in concentration-dependent increases in frequencies of MNBN cells. In the absence 
of S9-mix, micronucleus frequency increases were statistically significant (p ≤ 0.05) at the highest two 
selected concentrations compared to the concurrent control.  At the concentration of 120 μg/ml only a 
single replicate exceeded  the  historical control range. In the presence of S9-mix, statistically 
significant (p ≤  0.001) increases in MNBN frequencies were observed at 150 μg/ml  and above 
compared to concurrent vehicle controls, but exceeded the historical range at the top two 
concentrations and in a single replicate at 150 μg/ml. 
Cultures were also treated for 24 + 0 hours in the absence of S9-mix at concentrations of 10, 15, 16 
and 18 μg/ml (with cytotoxicity of 8, 32, 45 and 52 %, respectively), selected from the second of two 
trials. The first trial conducted at a concentration range of 1 - 17.5 μg/ml of 1-(4-methoxyphenyl)pent-
1-en-3-one resulted in insufficient toxicity (up to 40 % at the top concentration) and the second trial 
covered the range 2 - 25  μg/ml  and provided adequate cytotoxicity range. Although increases in 
MNBN cells were statistically significant at the lowest and one intermediate concentration (10 and 16 
μg/ml) compared to concurrent control cultures, frequencies of MNBN cells at all concentrations fell 
within normal ranges based on historical control data. Therefore, these data indicate absence of 
micronucleus induction. 
In conclusion, 1-(4-methoxyphenyl)pent-1-en-3-one induced micronuclei in cultured human peripheral 
blood lymphocytes when tested up to the limits of cytotoxicity for 3 + 21 hours in the presence of rat 
liver metabolic activation (S9-mix) and weakly in the absence of metabolic activation. It did not 
induce micronuclei in cells treated for 24 + 0 hours in the absence of S9-mix  up to toxic 
concentrations. 
2.2.  In vivo Genotoxicity Tests 
There are no new relevant studies available. 
CONCLUSION 
The two representative substances for subgroup 3.2 of FGE.19,  4-phenylbut-3-en-2-one  [FL-no: 
07.024] and 1-(4-methoxyphenyl)pent-1-en-3-one [FL-no:  07.030] showed an  in vitro  genotoxic 
potential. 4-Phenylbut-3-en-2-one [FL-no:  07.024] induced reproducible, concentration-related and 
statistically significant increases in the mutation frequencies, in strain TA100 of S. typhimurium in the 
presence of metabolic activation. It also induced micronuclei in cultured human peripheral blood 
lymphocytes when tested up to the limits of cytotoxicity for 3 + 21 hours in the absence and presence 
of rat liver metabolic activation (S9-mix).  Similarly, 1-(4-methoxyphenyl)pent-1-en-3-one [FL-no: 
07.030] did not induce gene mutation in bacteria. It induced micronuclei in cultured human peripheral 
blood lymphocytes when tested up to the limits of cytotoxicity for 3 + 21 hours in the presence of rat 
liver metabolic activation (S9-mix) and a weak increase in its absence. On this basis, to further assess 
the genotoxic potential of both representative substances (4-phenylbut-3-en-2-one [FL-no: 07.024] and 
1-(4-methoxyphenyl)pent-1-en-3-one [FL-no: 07.030]) of subgroup 3.2 of FGE.19, a combined in vivo 
micronucleus and Comet assays in liver and duodenum are requested. Flavouring Group Evaluation 215 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in 
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity
(e) 
02.066 
819 
4-Phenylbut-3-en-2-ol 
OH
(E)-isomer shown  
2880 
2032 
17488-65-2 
Liquid 
C10H12O 
148.21 
Insoluble 
Miscible 
140 (16 hPa) 
 
IR 
96 % 
1.558-1.567 
1.006-1.012 
07.024 
820 
4-Phenylbut-3-en-2-one 
O
(E)-isomer shown  
2881 
158 
122-57-6 
Solid 
C10H10O 
146.19 
Insoluble 
Very soluble 
260 
39-42 
IR 
97 % 
n.a. 
n.a. 
07.027 
821 
3-Methyl-4-phenylbut-3-en-
2-one 
O
(E)-isomer shown  
2734 
161 
1901-26-4 
Solid 
C11H12O 
160.22 
Insoluble 
Very soluble 
124-125(13 hPa) 
38-40 
NMR 
97 % 
n.a. 
n.a. 
07.030 
826 
1-(4-Methoxyphenyl)pent-1-
en-3-one 
O
O
(E)-isomer shown  
2673 
164 
104-27-8 
Solid 
C12H14O2 
190.24 
Insoluble 
Very soluble 
278 
60 
IR 
98 % 
n.a. 
n.a. 
07.046 
732 
Vanillylidene acetone    
HO
(E)-isomer shown
O
O
 
3738 
691 
1080-12-2 
Solid 
C11H12O3 
192.21 
Slightly soluble 
Moderately 
soluble 
 
129-130 
IR 
97 % 
n.a. 
n.a. 
07.049 
829 
1-(4-Methoxyphenyl)-4-
methylpent-1-en-3-one 
O
O
(E)-isomer shown  
 
3760 
719 
103-13-9 
Liquid 
C13H16O2 
204.27 
Insoluble 
Miscible 
201 (13 hPa) 
 
NMR 
97 % 
1.510-1.515 
1.016-1.026 Flavouring Group Evaluation 215 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in 
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity
(e) 
07.206 
 
4-(2,3,6-
Trimethylphenyl)but-3-en-2-
one   
 
(E)-isomer shown
O
 
 
 
56681-06-2 
Solid 
C13H16O 
188.27 
Practically 
insoluble or 
insoluble 
Freely soluble 
97 (0.1 hPa) 
75 
MS 
95 % 
n.a. 
n.a. 
(a):  Solubility in water, if not otherwise stated.  
(b):  Solubility in 95 % ethanol, if not otherwise stated.  
(c):  At 1013.25 hPa, if not otherwise stated. 
(d):  At 20°C, if not otherwise stated. (e): At 25°C, if not otherwise stated. 
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SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE  
Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-
no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
 
Class 
(b) 
Evaluation 
procedure path 
(c) 
JECFA Outcome 
on the named 
compound 
(d) or (e) 
EFSA conclusion on the named 
compound:   
02.066 
819 
4-Phenylbut-3-en-2-ol 
OH
(E)-isomer shown  
2.3 
0.1 
Class I 
A3: Intake below 
threshold 
(d)  Evaluated in FGE.215, additional 
genotoxicity data required 
07.024 
820 
4-Phenylbut-3-en-2-one 
O
(E)-isomer shown  
2.4 
7 
Class I 
A3: Intake below 
threshold 
(d)  Evaluated in FGE.215, additional 
genotoxicity data required 
07.027 
821 
3-Methyl-4-phenylbut-3-en-2-
one 
O
(E)-isomer shown  
0.12 
0.1 
Class I 
A3: Intake below 
threshold 
(d)  Evaluated in FGE.215, additional 
genotoxicity data required 
07.030 
826 
1-(4-Methoxyphenyl)pent-1-
en-3-one 
 
O
O
(E)-isomer shown  
0.37 
110 
Class I 
A3: Intake below 
threshold 
(d)  Evaluated in FGE.215, additional 
genotoxicity data required 
07.046 
732 
Vanillylidene acetone   
HO
(E)-isomer shown
O
O
 
0.11 
0.1 
Class I 
A3: Intake below 
threshold 
(d)  Evaluated in FGE.215, additional 
genotoxicity data required Flavouring Group Evaluation 215 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-
no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
 
Class 
(b) 
Evaluation 
procedure path 
(c) 
JECFA Outcome 
on the named 
compound 
(d) or (e) 
EFSA conclusion on the named 
compound:   
07.206 
 
4-(2,3,6-Trimethylphenyl)but-
3-en-2-one 
 
(E)-isomer shown
O
 
0.0012 
 
Class I 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.215, additional 
genotoxicity data required 
07.049 
829 
1-(4-Methoxyphenyl)-4-
methylpent-1-en-3-one 
 
O
O
(E)-isomer shown  
28 
0.3 
Class II 
A3: Intake below 
threshold 
(d)  Evaluated in FGE.215, additional 
genotoxicity data required 
(a):  EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
(b):  Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c):  Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d):  No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e):  Data must be available on the substance or closely related substances to perform a safety evaluation. 
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GENOTOXICITY DATA 
Table 5:   Genotoxicity Data in vitro Considered by the Panel in FGE.215 
Register name  
[FL-no]  
Test System   Test Object   Concentration   Result   Reference   Comments 
4-Phenylbut-3-en-2-
one 
[07.024] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA1535, TA1537 and 
TA102 
1.6, 8, 40, 200, 1000 
and 3000 μg/plate [1,2] 
Negative  Lillford, 2009  Evidence of toxicity was observed at 3000 μg/plate in 
TA100 in the  absence  of  S9-mix  and in all other 
strains  in the absence and presence of S9-mix; at 
1000 μg/plate in strain TA1535 in the absence of S9-
mix; complete killing was observed at 5000 μg/plate 
in strain  TA100 in the presence of S9-mix. 
Statistically significant concentration-related increase 
in  mutations was observed in strain  TA100 at 40 
μg/plate and above in the presence of S9-mix. Study 
design  complies  with current  recommendations 
(OECD Guideline 471). Acceptable top 
concentration was achieved. 
 
S. typhimurium TA100 
 
1.6, 8, 40, 200, 1000 
and 3000 μg/plate [4,2] 
 
1.6, 8, 40, 200, 1000 
and 5000 μg/plate [5,2]      
 
Negative 
 
 
Positive 
S. typhimurium TA98, 
TA1535, TA1537, 
TA102 
93.75, 187.5, 375, 750, 
1500 and 3000 μg/plate 
[4, 2] or [5,3] 
Negative  Evidence of  toxicity was observed at  750 and/or 
1500 and/or 3000 μg/plate  in the absence and 
presence of S9-mix.  Statistically significant 
concentration-related  increase in  mutations was 
observed only in strain TA100 at 375 μg/plate and 
above in  the presence of S9-mix. Study design 
complies  with current  recommendations  (OECD 
Guideline 471). Acceptable top  concentration was 
achieved. 
 
S. typhimurium TA100 
 
93.75, 187.5, 375, 750, 
1500 and 3000 μg/plate 
[4, 2] or [5,3] 
 
Positive [5,3] 
S. typhimurium TA98, 
TA1535, TA1537, 
TA102 
46.88, 93.75, 187.5, 
375, 750 and 1500 
μg/plate [5,3] 
Negative  Evidence of cytotoxicity was  observed at 1500 
μg/plate in all  strains. Statistically significant 
concentration-related  increase in mutations was 
observed only in strain TA100 at 187.5 μg/plate and 
above.  Study design complies  with current 
recommendations  (OECD Guideline 471). 
Acceptable top concentration was achieved. 
 
S. typhimurium TA100 
 
46.88, 93.75, 187.5, 
375, 750 and 1500 
μg/plate [5,3] 
 
Positive 
Micronucleus 
Induction 
Human peripheral blood 
lymphocytes 
30, 40 and 50  μg/ml 
[4,6] 
Negative  Stone, 2011  Although  acceptable levels of cytotoxicity were 
achieved at the top concentrations used in all parts of 
the study  and the  MNBN  cell frequencies were 
similar to vehicle controls in all treated cultures, the 
40, 70, 80 and 85 μg/ml 
[5,6] 
Negative Flavouring Group Evaluation 215 
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Register name  
[FL-no]  
Test System   Test Object   Concentration   Result   Reference   Comments 
      12, 14, 17.5 and 20 
μg/ml [4,7] 
Negative     inconsistent cytotoxicity curves generated among the 
three trials in this study  could not be easily 
explained. On this  basis a second study was 
performed (Watters, 2013). The study complies with 
OECD Guideline 487.  
30, 40, 44, and 46 
μg/ml [4,6] 
Positive  Watters, 2013  Acceptable levels of cytotoxicity  were achieved at 
the top concentrations used in all parts of the study. 
Test compound induced micronuclei in cultured 
human peripheral blood lymphocytes from both male 
and female donors, following 3+21 hours treatment 
in the absence and  presence of S9-mix.  The study 
complies with OECD Guideline 487. 
85, 95, 100, and 105 
μg/ml [5,6] 
Positive 
8, 13, 14 and 15 μg/ml 
[4,7] 
Negative 
1-(4-Methoxyphenyl) 
pent-1-en-3-one 
[07.030] 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, 
TA1537 and TA102 
0,32, 1.6, 8, 40, 200, 
1000 and 5000 μg/plate 
[1,2] 
Negative  Bowen, 2011  Toxicity was observed in the form of slight thinning 
of background bacteria lawn and reduced numbers of 
revertants at 1000 μg/plate in strains  TA1537  and 
TA102 and complete killing of bacteria was observed 
at  5000  μg/plate in all strains, in the  absence and 
presence of S9-mix. Study  design complies  with 
current  recommendations  (OECD Guideline 471). 
Acceptable top concentration was achieved.  
S. typhimurium TA98, 
TA100, TA1535  
 
 
 
156.3,  312.5, 625, 
1250,  2500 and 5000 
μg/plate [4,2] or [5,3] 
 
 
Negative  Evidence of toxicity was observed at  625  μg/plate 
and above in strains TA1535, TA1537 and TA102 in 
the presence of S9-mix, at 1250 μg/plate and above 
in strains TA1537 and TA102 in the absence of S9-
mix and TA100 in the presence of S9-mix, and at 
2500  μg/plate  and above in strains TA98 in  the 
absence and presence of S9-mix, and  TA100 and 
TA1535 in the absence of  S9-mix. Study design 
complies  with  current recommendations  (OECD 
Guideline 471). Acceptable  top concentration was 
achieved.  
S. typhimurium TA1537 
and TA102 
78.13,  156.3, 312.5, 
625, 1250, 2500 and 
5000  μg/plate [4,2]  or 
[5,3] 
Negative 
S. typhimurium TA1535 
and TA1537 
19.53, 39.06, 78.13, 
156.3, 312.5, 625, 1250 
and 2500 μg/plate [5,3] 
Negative  Evidence of toxicity was observed at 625 μg/plate 
and above in both strains.  
Micronucleus 
Induction 
Human peripheral blood 
lymphocytes 
60, 100, 110, 120  and 
130 μg/ml [4,6] 
Positive (weak)  Stone, 2012  In pulse treatment with recovery in the absence of 
S9-mix, MNBN cell frequency was higher than the 
historical range only at the highest concentration. In 
the presence of S9-mix, statistically significant 
90, 150, 160 and  180 
μg/ml [5,6] 
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Register name  
[FL-no]  
Test System   Test Object   Concentration   Result   Reference   Comments 
      10, 15, 16 and 18 μg/ml 
[4,7] 
Negative     increases in MNBN were observed from 150 μg/ml 
and above and exceeded the historical range at the 
top two concentrations and a single replicate of 150 
μg/ml. After 24 hours treatment without S9-mix, all 
frequencies were  within historical control range 
although statistically significant increases in MNBN 
cells were observed at 10 and 16 μg/ml. Study design 
complies with OECD Guideline 487. Acceptable 
levels of cytotoxicity  were achieved at the top 
concentrations in all parts of the study. 
[1]   With and without S9-mix metabolic activation. 
[2]   Plate incorporation method. 
[3]   Pre-incubation method. 
[4]   Without S9-mix metabolic activation. 
[5]   With S9-mix metabolic activation. 
[6]   3-hour incubation with 21-hour recovery period. 
[7]   24-hour incubation with no recovery period. 
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ABBREVIATIONS 
CAS    Chemical Abstract Service 
CEF    Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE    Council of Europe 
EFFA    European Flavour Association 
EFSA    The European Food Safety Authority 
EU    European Union 
FGE    Flavouring Group Evaluation 
FLAVIS (FL)  Flavour Information System (database) 
GLP    Good Laboratory Practice 
ID    Identity 
IOFI    International Organization of the Flavor Industry 
IR    Infrared spectroscopy 
JECFA   Joint FAO/WHO Expert Committee on Food Additives 
MN    Micronuclei 
MNBN   MicroNucleated BiNucleate cells 
MS    Mass spectra 
MSDI    Maximised Survey-derived Daily Intake 
NMR    Nuclear Magnetic Resonance 
No    Number 
OECD    Organisation for Economic Co-operation and Development 
(Q)SAR  (Quantitative ) Structure Activity Relationship 
WHO    World Health Organization 